Adalimumab Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Biologics, Biosimilars), By Therapeutic Area (Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis, Crohn’s Disease, Others), By Region and Competition, 2020-2030F

Market Overview

Global Adalimumab Market was valued at USD 2.72 Billion in 2024 and is expected to reach USD 3.56 Billion by 2030 with a CAGR of 4.80%. Adalimumab, a monoclonal antibody that inhibits tumor necrosis factor-alpha (TNF-α), is widely prescribed for conditions such as rheumatoid arthritis, psoriasis, Crohn’s disease, ulcerative colitis, and ankylosing spondylitis. Its effectiveness in reducing inflammation and halting disease progression has made it a cornerstone therapy in immunology.

One of the primary growth drivers is the rising global burden of autoimmune and chronic inflammatory disorders. With the aging population and the growing awareness of advanced treatment options, there has been a notable uptick in diagnosis and treatment rates. Additionally, the increasing healthcare expenditure across emerging markets is enhancing access to biologic therapies, including adalimumab. While price competition will remain intense, especially in mature markets, the overall rise in treatment demand and global access will sustain market expansion over the forecast period.

Key Market Drivers

Growth in Healthcare Industry

The global healthcare industry generates annual revenues exceeding USD 4 trillion. Among its most significant and lucrative segments are pharmaceuticals and biotechnology, accounting for nearly USD 850 billion, followed by medical technology and diagnostics, which contribute over USD 400 billion. The robust expansion of the global healthcare industry is playing a pivotal role in propelling the growth of the adalimumab market. As healthcare systems across both developed and emerging economies continue to evolve, there is a notable increase in the diagnosis and treatment of chronic autoimmune conditions such as rheumatoid arthritis, Crohn’s disease, psoriatic arthritis, and ankylosing spondylitis key indications for which adalimumab is prescribed. Enhanced diagnostic capabilities, supported by growing investments in healthcare infrastructure, are enabling earlier and more accurate detection of these conditions, thereby increasing the demand for targeted biologic therapies like adalimumab.

In addition, rising healthcare expenditure fueled by government funding, private investment, and the expansion of insurance coverage is making advanced treatments more accessible to a broader patient population. In 2021, global healthcare expenditure reached an impressive USD 9.8 trillion, representing approximately 10.3% of the global GDP. Despite this significant investment, life expectancy has remained stagnant over the past decade in several countries, including the United States, where annual healthcare spending exceeds USD 4 trillion. This is particularly evident in emerging markets, where health policy reforms and expanding hospital networks are improving patient access to biologics. Adalimumab, being a widely adopted tumor necrosis factor (TNF) inhibitor, benefits directly from this increased access to advanced therapies.

Surge in Technological Advancements

The global adalimumab market is experiencing notable growth, significantly driven by continuous technological advancements in biotechnology and drug delivery systems. In 2022, a nanoparticulate delivery platform was engineered through covalent crosslinking of the anti-TNF-α antibody adalimumab (ADA) to the particle surface. This approach enhanced ADA’s stability against proteolytic degradation in vitro and demonstrated a markedly improved therapeutic efficacy in a murine model of colitis. These innovations have enhanced the development, manufacturing, and administration of monoclonal antibodies, including adalimumab, a leading therapeutic agent used to treat autoimmune disorders such as rheumatoid arthritis, Crohn's disease, and psoriasis.

One of the primary areas of progress is the evolution of bioengineering techniques that allow for improved molecular design and higher production efficiency. Advanced recombinant DNA technology has facilitated the creation of biosimilars with high therapeutic efficacy and lower development costs, expanding patient access and encouraging market competition. Additionally, improvements in cell line development and bioprocessing methods have led to increased yield and product consistency, supporting the scalability of adalimumab production to meet growing global demand.

Download Free Sample Report

Key Market Challenges

High Cost of Production

One of the most significant challenges facing the global adalimumab market is the high cost of production associated with biologic therapies. Adalimumab, being a complex monoclonal antibody, requires sophisticated biotechnological processes for its development, manufacturing, and quality control. These processes involve substantial investment in specialized facilities, skilled personnel, and stringent regulatory compliance measures, all of which contribute to elevated production costs.

Unlike conventional small-molecule drugs, the manufacturing of adalimumab involves the use of living cells and highly controlled environments to ensure product consistency, potency, and safety. The upstream and downstream processes, including cell culture, purification, and formulation, are capital-intensive and time-consuming. Moreover, the risk of batch failure and the need for extensive validation further increase the cost burden on manufacturers.

Key Market Trends

Rising Prevalence of Chronic Diseases

The increasing prevalence of chronic diseases, particularly autoimmune and inflammatory disorders, has emerged as a defining trend in the global adalimumab market. Conditions such as rheumatoid arthritis, ulcerative colitis, plaque psoriasis, and Crohn’s disease are on the rise, driven by factors including aging populations, sedentary lifestyles, dietary habits, and environmental triggers. This growing disease burden has created a sustained demand for advanced biologic therapies, positioning adalimumab as a critical component in the long-term management of these conditions.

As autoimmune disorders often require ongoing treatment to manage symptoms and prevent disease progression, the demand for highly effective and targeted biologics like adalimumab continues to grow. With its broad spectrum of approved indications and a well-established safety and efficacy profile, adalimumab remains a preferred therapeutic option among clinicians for managing chronic inflammation-related conditions. Adalimumab is the first fully human monoclonal antibody targeting tumor necrosis factor (TNF) to be approved for the treatment of rheumatoid arthritis (RA). Clinical studies have confirmed its safety and efficacy for the long-term management of RA in patients.

Segmental Insights

Type Insights

Based on Type, Biologics have emerged as the fastest growing segment in the Global Adalimumab Market in 2024. This is largely due to their superior efficacy, targeted mechanism of action, and expanding applications in the treatment of chronic autoimmune diseases. As a biologic drug itself, adalimumab represents a paradigm shift from conventional small-molecule therapies to more precise, protein-based treatments that interact directly with specific components of the immune system. Additionally, advancements in biomanufacturing technologies and delivery systems have made biologic therapies more convenient and scalable.

Therapeutic Area Insights

Based on Therapeutic Area, Psoriasis have emerged as the fastest growing segment in the Global Adalimumab Market during the forecast period. The global burden of psoriasis, particularly moderate to severe forms, has been steadily increasing, prompting greater demand for effective long-term treatment solutions. Adalimumab, a TNF-α inhibitor, has demonstrated high efficacy and safety in managing chronic plaque psoriasis, leading to its growing adoption among dermatologists. Furthermore, the introduction of biosimilar versions has made the therapy more accessible and affordable in several markets, especially in developing economies.

Download Free Sample Report

Regional Insights

Based on Region, North America have emerged as the dominating region in the Global Adalimumab Market in 2024. This is due to a combination of high healthcare expenditure, advanced medical infrastructure, and early access to biologic therapies. The presence of major pharmaceutical players, including AbbVie, the original developer of Humira has further strengthened the region’s leadership. Additionally, widespread awareness and diagnosis of autoimmune conditions such as rheumatoid arthritis, psoriasis, and Crohn’s disease have significantly contributed to elevated prescription volumes.

Recent Development

• In April 2025, Celltrion, Inc. announced that the U.S. Food and Drug Administration (FDA) granted interchangeable status to YUFLYMA, a biosimilar to Humira (adalimumab). YUFLYMA is an FDA-approved, high-concentration (100 mg/mL), citrate-free formulation indicated for the treatment of various inflammatory conditions. The interchangeable designation was based on results from a Phase III study, which demonstrated comparable pharmacokinetics, efficacy, safety, and immunogenicity between patients with moderate to severe plaque psoriasis who either continued treatment with reference adalimumab or switched between reference adalimumab and YUFLYMA during the Week 25–27 dosing interval.
• In May 2024, Teva Pharmaceuticals, the U.S. affiliate of Teva Pharmaceutical Industries Ltd., in partnership with Alvotech, announced the launch of SIMLANDI (adalimumab-ryvk) injection in the United States. Approved by the U.S. Food and Drug Administration (FDA), SIMLANDI is the first high-concentration, citrate-free biosimilar to Humira granted interchangeability exclusivity for the 40mg/0.4mL formulation. It is indicated for the treatment of multiple conditions, including adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adult ankylosing spondylitis, Crohn’s disease, adult ulcerative colitis, adult plaque psoriasis, adult hidradenitis suppurativa, and adult uveitis.
• In May 2025, Samsung Bioepis Co., Ltd. and Organon & Co. announced that the U.S. Food and Drug Administration (FDA) had granted interchangeability status to the high- and low-concentration (40 mg/0.4 mL, 40 mg/0.8 mL) autoinjectors and the high-concentration prefilled syringe of HADLIMA (adalimumab-bwwd), establishing them as interchangeable biosimilars to Humira (adalimumab). This decision builds upon the FDA’s previous designation in June 2024, which recognized the HADLIMA low-concentration (40 mg/0.8 mL) prefilled syringe and single-dose vial as interchangeable. The interchangeability designation permits pharmacists, subject to state pharmacy regulations, to substitute the biosimilar for the reference biologic without requiring prescriber authorization.
• In March 2024, JAMP Pharma announced the launch of Jamteki, the first ustekinumab biosimilar to Janssen’s Stelara in the Canadian market. Approved by Health Canada in November 2023, the launch follows a recent settlement between Alvotech and Johnson & Johnson concerning ustekinumab. Developed by Alvotech, Jamteki marks JAMP Pharma’s second biosimilar introduction in Canada within two years, following the 2022 launch of Simlandi, a biosimilar of AbbVie’s Humira (adalimumab). Jamteki is available in 45mg/0.5mL and 90mg/mL pre-filled syringes, equipped with a passive safety device for subcutaneous administration.

Key Market Players

• AbbVie Inc.
• Pfizer, Inc.
• Amgen Inc.
• Novartis AG
• Torrent Pharmaceuticals Ltd.
• Cadila Healthcare Limited
• Boehringer Ingelheim International GmbH
• Mylan N.V.
• Hetero Biopharma Ltd
• Samsung Bioepis Co Ltd.

Report Scope

In this report, the Global Adalimumab Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Adalimumab Market, By Type:

o   Biologics

o   Biosimilars

• Adalimumab Market, By Therapeutic Area:

o   Rheumatoid Arthritis

o   Psoriatic Arthritis

o   Psoriasis

o   Crohn’s Disease

o   Others

• Adalimumab Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Adalimumab Market.

Available Customizations:

Global Adalimumab Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Adalimumab Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]